© Rosalind Scientific LLC 2018-2022
© Rosalind Scientific LLC, 2018-2022
New Drug Hunter content, featured events and job postings straight to your inbox. Trusted by >3,500 drug hunters worldwide, unsubscribe anytime.
<< Back to August
TYK2-selective kinase inhibitor (JH1 domain)
in Ph. II for inflamm. conditions (oral, QD)
from structure-based design
J. Med. Chem., Aug. 5, 2020
Pfizer, Cambridge, MA / Groton, CT
PF-06826647 is a TYK2-selective kinase inhibitor which binds to the catalytically active JH1 kinase domain, in contrast to BMS-986165, a TYK2 inhibitor in Ph. III for psoriasis that binds to…
Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.